Mumbai, Nov 12 (UNI) Veeda CR, India's fastest growing Clinical Research Organisation (CRO), has received approvals from the USFDA (US Food and Drug Association), WHO (World Health Organisation) and ANVISA (Brazilian Regulatory Authority).
Veeda CR Group managing director and founder Binoy Gardi said '' These regulatory approvals have merely verified and validated the high quality of work we do at Veeda.'' Apurva Shah Group Managing Director and founder said ''Quality is the cornerstone of Veeda. From day one we ensured that not only are our facilities of the highest standard but so is the calibre of our people. This is why we continue to get work from 9 of the top 15 Global Pharmaceutical companies.'' Veeda has received approval for 6 studies from the USFDA, which is one of the most credible regulatory authorities of the world.
Getting as many as 6 Bioequivalence study approvals from USFDA without any 483's has really enhanced Veeda's reputation in the industry. Simultaneously, Veeda has also been successful in getting a nod from WHO for one of its studies.
ANVISA (Brazilian Regulatory Body) has re-qualified Veeda's Bioequivalence centre for the second consecutive year, which enables Veeda to continue conducting studies for drugs to be marketed in Brazil.